You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Cellular therapies
114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020218024
Dec 20201804
Jan 20215003
Feb 20212006
Mar 202144011
Apr 20215007
May 2021805
Jun 20210010
Jul 20210019
Aug 20210024
Sep 20210016
Oct 202153025
Nov 202130016
Dec 20211803
Jan 20223809
Feb 20223408
Mar 20222001
Apr 20225005
May 202270016
Jun 202237011
Jul 20221201
Aug 20225207
Sep 202235012
Oct 20222207
Nov 20222604
Dec 20222201
Jan 20231003
Feb 20234005
Mar 20231402
Apr 20232402
May 2023600
Jun 20231201
Jul 20231406
Aug 2023204
Sep 2023604
Oct 2023801
Nov 20233006
Dec 20232201
Jan 2024601
Feb 20242003
Mar 202422020
Apr 20243409
May 20241204
Jun 20242202
Jul 20241404
Aug 20241803
Sep 20241203
Oct 202422012
Nov 20241009
Dec 2024407
Jan 20251406
Feb 2025005
Mar 2025009
Apr 2025005
May 2025009
Jun 2025004
Total13250405